After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last month.
The companies plan to spin off Actelion’s research and development pipeline into a new company, led by Actelion CEO Jean-Paul Clozel.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson to pay $30B for Actelion appeared first on MassDevice.
from MassDevice http://ift.tt/2kwR57Y
Cap comentari:
Publica un comentari a l'entrada